Abstract:Since the establishment of bacteria-laden plaque as a causative agent in gingivitis, the search for specific bacteria that induce different types of periodontitis has generated extensive research. In contrast to many other microbial-induced disorders, the specific periodontal pathogen(s) has not been identified to date. Therefore, the search for an effective systemic agent to prevent the loss of attachment through the selective reduction of known periodontal pathogens has remained elusive. It is not surprising then that antibiotics are not used solely to manage periodontal diseases but rather as an adjunct to the mechanical débridement of root surfaces in select periodontal diseases. Further, the sole use of antibiotics in patients with adult periodontitis (or those who exhibit signs of inflammation but are periodontally stable) has shown little benefit and only increases the chance of microbial resistance to antibiotics. Despite these limitations, considerable progress in antibiotic therapy has delivered regimens that enhance the effectiveness of conventional therapy. In contrast to traditional antimicrobial therapy, new treatment modalities have begun to focus on modulating the responses of host cells to bacteria rather than modulating only the bacteria. Current drugs used to regulate host cells inhibit the cyclooxygenase pathway, reduce the activity of metalloproteinases, or inactivate bone resorptive cells (see Table 1). Although these drugs offer great potential to modulate a variety of mammalian cells, a notable and consequential limitation of these agents is a lack of specificity. Inflammation, bone metabolism, and connective tissue metabolism are two-edged swords; all are necessary for the homeostasis of the tissue, but some or all may also be involved in the pathologic destruction of that same tissue. Hence, drugs that inhibit destruction of the connective tissue in one site of the periodontium also interfere with wound healing at another. As a result of these limitations, the efficacy, safety, and cost-effectiveness of the long-term use of these agents is unknown. Preliminary results of treatment with these drugs are promising, and future generations of host-modulating drugs will provide clinicians with additional agents to help improve the success rate of periodontal treatment for patients. Antibiotics remain an important adjunctive therapy in the treatment of periodontal diseases, and the use of host modulating drugs as supplemental agents in the management of periodontal diseases continues to grow. As more knowledge is gained about the causes of periodontal diseases, new drugs that are potent, effective, site specific, and safe can be delivered at optimal times by simply having the patient take a few tablets. Considering the dramatic progress in the past decade in understanding the cause and pharmacologic management of periodontal diseases, the twenty-first century holds great promise for the development of magic bullets.

The role of controlled drug delivery for periodontitis. The Research, Science and Therapy Committee of the American Academy of Periodontology.

Principles and Clinical Applications of Periodontal Controlled Drug Delivery with Tetracycline Fibers.

Local Delivery and Controlled Release Drugs Systems: A New Approach for the Clinical Treatment of Periodontitis Therapy

Controlled drug release in periodontics: a review of new therapies

Local drug delivery systems as therapeutic strategies against periodontitis: A systematic review

Comparative Assessment of the Effect of Three Various Local Drug Delivery Medicaments in the Management of Chronic Periodontitis

A Controlled Multicenter Study Of Adjunctive Use Of Tetracycline Periodontal Fibers In Mandibular Class Ii Furcations With Persistent Bleeding

Impact of local drug delivery and natural agents as new target strategies against periodontitis: new challenges for personalized therapeutic approach

Dental Drug Delivery System used in Periodontitis

Local Delivery Of Tetracycline: From Concept To Clinical Application

Periodontal Gel For The Targeted Drug Delivery In The Periodontal Cavity For Management Of Periodontitis And Gingivitis

Evaluation of a novel local drug delivery system containing tetracycline hydrochloride microparticles as an adjunct to mechanotherapy in the management of chronic periodontitis

Local delivery of terracycline: from concept to clinical application*

Clinical efficacy of subgingivally delivered 0.5% controlled release azithromycin gel in the management of chronic periodontitis

Pharmacologic management of periodontal diseases using systemically administered agents

Microbiological and Clinical Evaluation of Efficacy of Locally Delivered Tetracycline in Conjunction with Scaling and Root Planning

In situ gel drug delivery system for periodontitis: an insight review

Effectiveness of Conventional Periodontal Treatment With Tetracycline Fiber Versus Minocycline Gel Application Subgingivally in Periodontitis Patients

Local Delivery Antimicrobials for Chronic Periodontitis

Biological approaches to the development of novel periodontal therapies--consensus of the Seventh European Workshop on Periodontology.